中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 增加 2024 年度日常关联交易预计的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海 仁度生物科技股份有限公司（以下简称"仁度生物"或"公司"）的保荐机构，根据 《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海 证券交易所上市公司自律监管指引第 11 号——持续督导》《上海证券交易所上市公司 自律监管指引第 5 号——交易与关联交易指引（2023 年修订）》等有关法律、行政法 规、部门规章及业务规则的要求，对仁度生物增加 2024 年度日常关联交易预计事项进 行了认真、审慎核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 上海仁度生物科技股份有限公司（以下简称"公司"）于 2024 年 6 月 24 日召开 第二届董事会第七次会议审议通过了《关于增加 2024 年度日常关联交易预计的议 案》，表决结果为：赞成 7 票，无反对票，无弃权票。 本次日常关联交易为公司的子公司泰州智量医学检验有限公司（以下简称"泰州 智量"）向常州瑞鸿医院有限公司实验室提供医学检验和 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-033 上海仁度生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/23 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 6 个月 | | 预计回购金额 | 元~50,000,000 元 25,000,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 股 804,169 | | 累计已回购股数占总股本比例 | 2.0104% | | 累计已回购金额 | 23,371,319.49 元 | | 实际回购价格区间 | 26.31 元/股~30.55 元/股 | 一、 回购股份的基本情况 公司于 2024 年 2 月 18 日召开第二届董事会第三次会议，审议通过了《关于 以集中竞价交易方式回购 ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 2023 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法 规的规定，中国国际金融股份有限公司（以下称"保荐机构"）作为上海仁度生物科技 股份有限公司（以下简称"仁度生物"或"公司"）持续督导工作的保荐机构，负责仁 度生物上市后的持续督导工作，并出具 2023 年度持续督导跟踪报告，本持续督导期间 为 2023 年 1 月 1 日至 2023 年 12 月 31 日。 一、持续督导工作情况 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并 针对具体的持续督导工作制定相应的工作计 | 保荐机构已建立健全并有效执行了持续督导 | | | | 制度，并制定了相应的工作计划。 | | | 划。 | | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与仁度生物签订《保荐协议》，该 协议明确了双方在持续督导期间的权利和义 | | ...

| 回购方案首次披露日 | 2024/2/23 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 6 个月 | | 预计回购金额 | 元~50,000,000 元 25,000,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 股 804,169 | | 累计已回购股数占总股本比例 | 2.0104% | | 累计已回购金额 | 23,371,319.49 元 | | 实际回购价格区间 | 26.31 元/股~30.55 元/股 | 证券代码：688193 证券简称：仁度生物 公告编号：2024-031 上海仁度生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 特此公告。 上海仁度生物科技股份有限公司 一、 回购股份的基本情况 公司于 2024 年 2 月 18 日召开第二届董事会第三次会议 ...

Financial Performance - The net profit attributable to shareholders for 2023 is RMB 8,259,296.58, with a distributable profit of RMB 109,585,010.34 as of December 31, 2023[6]. - The proposed cash dividend is RMB 2.00 per 10 shares, totaling RMB 7,839,166.20, which represents 94.91% of the net profit for the year[6]. - The company has not yet achieved profitability since its listing[4]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 25% year-over-year growth[21]. - The company's operating revenue for 2023 was ¥164,412,273.10, a decrease of 45.89% compared to ¥303,848,685.60 in 2022[24]. - The net profit attributable to shareholders for 2023 was ¥8,259,296.58, down 64.60% from ¥23,331,394.53 in 2022[24]. - The basic earnings per share decreased by 66.13% to ¥0.21 in 2023, compared to ¥0.62 in 2022[25]. - The company reported a net cash flow from operating activities of ¥17,191,765.24 in 2023, a significant recovery from a negative cash flow of ¥4,091,191.80 in 2022[24]. - The total assets at the end of 2023 were ¥1,054,715,696.08, a decrease of 3.12% from ¥1,088,721,710.38 at the end of 2022[24]. - The weighted average return on equity decreased to 0.86% in 2023, down from 2.97% in 2022, a decline of 2.11 percentage points[25]. Research and Development - Research and development expenses increased by 10%, totaling 150 million RMB, focusing on innovative diagnostic technologies[21]. - Research and development expenses increased by 20.31%, accounting for 25.02% of operating revenue, up from 11.25% in the previous year[27]. - The company has applied for 9 new invention patents and obtained 4 new invention patents during the reporting period, bringing the total number of patents to 58, including 32 invention patents and 26 utility model patents[76]. - The company’s core technology includes RNA real-time fluorescence isothermal amplification technology and multi-target RNA amplification detection technology, all of which are developed in-house[71]. - The company is focusing on the development of RNA molecular diagnostics, which is expected to reduce false positives and improve clinical compliance compared to DNA detection methods[70]. - The company has achieved a significant advancement in the automation of molecular diagnostics, with systems capable of completing the entire process in a closed environment, thus minimizing human error[70]. - The company has established a comprehensive product line that includes four proprietary nucleic acid testing kits for reproductive pathogens, four for respiratory pathogens, and three for intestinal viruses, all utilizing RNA real-time fluorescence isothermal amplification technology[87]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 15% market share within the next two years[21]. - The company is actively exploring the global molecular diagnostic market and leveraging digital economy opportunities to enhance its market presence[68]. - The company aims to expand its market presence through continuous innovation in diagnostic technologies and strategic partnerships[43]. - The company plans to enhance its R&D system, improve product quality, and integrate resources from multiple locations to boost innovation and efficiency[129]. - The marketing strategy includes expanding the overseas market and establishing a service ecosystem to enhance brand recognition and influence in developed countries[130]. Corporate Governance - The board of directors has approved the profit distribution plan, pending shareholder meeting approval[7]. - The company has established a governance framework with clear roles and responsibilities among shareholders, the board, and management to ensure compliance and effective operation[133]. - All resolutions from the shareholder meetings held in 2023 were approved without any rejections, indicating strong governance practices[136]. - The company has maintained a stable management team, with no changes in shareholding for the current directors[139]. - The company is committed to enhancing its corporate governance by appointing independent directors with diverse backgrounds[140]. Operational Risks and Challenges - The report includes a detailed discussion of various operational risks and corresponding mitigation measures[4]. - The company faces risks related to new product development, including potential delays and high costs, which could impact its competitive edge[91]. - The company must navigate regulatory challenges for third-class medical device registrations, which typically take 3-5 years to complete[92]. - The company is exposed to intensified market competition, with many new entrants in the rapidly growing in vitro diagnostics sector[94]. Social Responsibility and Environmental Impact - The company donated a total of 13.24 million yuan in cash and 13.84 million yuan in material contributions for charitable activities in 2023[192]. - The company has established a comprehensive environmental protection management system, detailing responsibilities and waste disposal regulations across departments[190]. - The company has taken measures to reduce carbon emissions, integrating energy-saving concepts into daily operations[191]. - The company is not listed as a key pollutant discharge unit and has complied with environmental regulations without any instances of exceeding discharge standards during the reporting period[186].

Financial Performance - The company's operating revenue for Q1 2024 was ¥44,815,148.38, representing a year-on-year increase of 15.60%[5] - Total revenue for Q1 2024 reached ¥44,815,148.38, an increase of 15.3% compared to ¥38,766,500.34 in Q1 2023[21] - Net profit for Q1 2024 was ¥3,703,907.82, a significant recovery from a net loss of ¥6,392,335.66 in Q1 2023[22] - Operating profit for Q1 2024 was ¥3,373,723.53, compared to an operating loss of ¥8,175,895.71 in the same period last year[21] - The company reported a total comprehensive income of ¥3,772,583.60 for Q1 2024, compared to a total comprehensive loss of ¥6,909,010.22 in Q1 2023[22] - Basic and diluted earnings per share for Q1 2024 were both ¥0.09, recovering from a loss of ¥0.16 per share in Q1 2023[22] Cash Flow and Operating Activities - The net cash flow from operating activities was ¥8,135,229.74, primarily due to reduced payments for material procurement compared to the previous year[9] - Cash flow from operating activities generated a net inflow of ¥8,135,229.74 in Q1 2024, reversing from a net outflow of ¥6,213,384.20 in Q1 2023[25] - The company experienced a net cash outflow of ¥19,657,841.28 in Q1 2024, compared to a net outflow of ¥25,697,122.20 in Q1 2023[26] Research and Development - Research and development expenses totaled ¥10,176,017.01, accounting for 22.71% of operating revenue, an increase of 0.74 percentage points[6] - Research and development expenses increased to ¥10,176,017.01 in Q1 2024, up from ¥8,518,167.13 in Q1 2023, reflecting a growth of 19.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,040,825,061.67, a decrease of 1.32% from the end of the previous year[6] - As of March 31, 2024, the company's total assets amounted to RMB 1,040,825,061.67, a decrease from RMB 1,054,715,696.08 as of December 31, 2023, reflecting a decline of approximately 1.3%[16] - The company's current assets totaled RMB 887,218,897.39, slightly down from RMB 899,141,593.82 at the end of 2023, indicating a decrease of about 1.4%[16] - The company's total liabilities decreased to RMB 84,756,877.05 from RMB 91,974,054.59, reflecting a decline of approximately 7.9%[18] - The equity attributable to shareholders decreased to RMB 956,068,184.62 from RMB 962,741,641.49, a decrease of about 0.7%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,063[10] - The top ten shareholders held a combined 56.92% of the company's shares, with the largest shareholder owning 19.65%[12] Inventory and Receivables - The company's inventory decreased to RMB 27,025,375.34 from RMB 28,595,133.59, indicating a decline of approximately 5.5%[16] - Accounts receivable decreased to RMB 69,604,041.39 from RMB 76,805,672.80, a reduction of about 9.4%[16] - The company reported a decrease in accounts payable to RMB 3,905,214.08 from RMB 4,093,721.67, a reduction of about 4.6%[17] Government Subsidies - The company received government subsidies amounting to ¥1,486,340.57, which are closely related to its normal business operations[7] Other Information - The company's short-term borrowings and other financial liabilities were not reported in the current quarter[18] - The company has not disclosed any significant new product developments or market expansion strategies in the current report[14]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024 年 5 月 22 日（星期三）下午 15:00 证券代码：688193 证券简称：仁度生物 公告编号：2024-026 上海仁度生物科技股份有限公司 关于参加上海辖区上市公司 2023 年报集体业绩说明会 暨 2024 年第一季度业绩说明会的公告 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 网 址 ： （https://roadshow.sseinfo.com/） 会议召开方式：线上文字互动 投资者可于 2024 年 5 月 15 日（星期三）至 5 月 20 日（星期一）16:00 前通过邮件、电话等形式将需要了解和关注的问题提前提供给公司。公司将在文 字互动环节对投资者普遍关注的问题进行回答。 上海仁度生物科技股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日发布公司《2023 年年度报告》以及《2024 年第一季度报告》，为便于广大投 资者更全面深入地了解公司经营成果、财务状况，公司计划于 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-021 上海仁度生物科技股份有限公司 关于以集中竞价交易方式回购公司股份比例 | 回购方案首次披露日 | 2024/2/23 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 6 个月 | | 预计回购金额 | 元~50,000,000 元 25,000,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 股 804,169 | | 累计已回购股数占总股本比例 | 2.0104% | | 累计已回购金额 | 23,371,319.49 元 | | 实际回购价格区间 | 26.31 元/股~30.55 元/股 | 一、 回购股份的基本情况 公司于 2024 年 2 月 18 日召开第二届董事会第三次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以不低于人民币 2,500 万元（含）且不超过人民币 5,000 万元（含）的自有资金，通过集中竞价交易方式 回购公司人民币 ...

一、监事会会议召开情况 证券代码：688193 证券简称：仁度生物 公告编号：2024-020 上海仁度生物科技股份有限公司 第二届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 特此公告。 上海仁度生物科技股份有限公司 监事会 2024 年 4 月 23 日 上海仁度生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日召开第二届监事会第三次会议（以下简称"本次会议"或"会议"），本次 会议的通知及会议材料于 2024 年 4 月 16 日通过邮件方式送达全体监事。本次 会议应出席监事 3 人，实际出席监事 3 人。全体监事一致同意推选吴伟良先生 主持本次会议。本次会议的通知、召开及审议程序符合《公司法》和《公司章 程》的有关规定，会议决议合法、有效。 二、监事会会议审议情况 经与会监事审议，一致通过如下议案： 1、审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议案》 监事一致认为：公司在确保募投项目所需资金和保 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-019 上海仁度生物科技股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海仁度生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日 召开第二届董事会第五次会议，审议通过了《关于使用闲置自有资金购买理财产 品的议案》，在确保不影响公司正常经营及资金安全的前提下，为提高公司资金 利用效率，同意公司（包括公司下属全资子公司，下同）2024 年拟使用总额度不 超过人民币 3 亿元闲置自有资金购买安全性高、流动性好、具有合法经营资格的 金融机构销售的理财产品（包括协定存款、定期存款、通知存款、大额存单、结 构性存款、收益凭证等），产品期限不超过 12 个月，该决议自董事会决议通过 之日起 12 个月内有效，在前述额度及期限范围内，公司可以循环滚动使用。董 事会授权董事长决定购买理财产品相关事宜、签署或授权财务负责人签署与购买 理财产品有关的各项法律文件，并办理相关手续，具体事项由公司财务部负 ...